REG - N4 Pharma PLC - Result of AGM

N4 PharmaAnnouncement

24/03/2021 10:45

RNS Number : 3304T
  
N4 Pharma PLC
  
24 March 2021
  
 

24 March 2021
N4 Pharma plc
("N4 Pharma" or the "Company")
 
Result of Annual General Meeting
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. The results of the proxy voting for the AGM are set out below.
 




Resolution (*Special Resolution)


Total Shares Voted


Shares


%




 


 


For


Against


For


Against





 


 


 


 


 


 




1. To receive the annual report and audited accounts for the year ended 31 December 2020 


20,289,075
 


20,222,189
 


66,886
 


99.67
 


0.33
 




2. To re-elect Chris Britten as a Director of the Company 


20,286,756
 


20,153,341
 


133,415
 


99.34
 


0.66
 




3. To re-elect Luke Cairns as a Director of the Company 


20,286,756
 


20,194,827
 


91,929
 


99.55
 


0.45
 




4. To re-elect John Chiplin as a Director of the Company 


20,286,756
 


20,209,370
 


77,386
 


99.62
 


0.38
 




5. To re-appoint Saffery Champness LLP as auditor to the company and authorise the directors to determine their remuneration 


20,219,901
 


20,134,176
 


85,725
 


99.58
 


0.42
 




6. To authorise the Directors to allot shares 


20,283,475
 


20,101,362
 


182,113
 


99.10
 


0.90
 




7*. To disapply pre-emption rights 


20,250,090
 


20,123,051
 


127,039
 


99.37
 


0.63
 



 
 
Enquiries:
 



N4 Pharma plc








Nigel Theobald, CEO 


Via IFC Advisory




Luke Cairns, Executive Director


















SP Angel Corporate Finance LLP


Tel: +44(0)20 3470 0470




Nominated Adviser and Joint Broker








Matthew Johnson/Caroline Rowe (Corporate Finance)








Vadim Alexandre/Rob Rees (Corporate Broking)


















Turner Pope Investments (TPI) Limited


Tel: +44(0)20 3657 0050




Joint Broker








Andy Thacker/Zoe Alexander


















IFC Advisory Ltd
Financial PR
Graham Herring
Zach Cohen                                                  


Tel: +44(0)20 3934 6630



 
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
RAGBGGDXBSDDGBS